Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

449 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study.
Caimi PF, Ai WZ, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, Stathis A, Zinzani PL, Wang Y, Qin Y, Wang L, Xu ZC, Carlo-Stella C. Caimi PF, et al. Among authors: hamadani m. Haematologica. 2024 Apr 1;109(4):1184-1193. doi: 10.3324/haematol.2023.283459. Haematologica. 2024. PMID: 37646659 Free PMC article. Clinical Trial.
In relapsed or refractory diffuse large B-cell lymphoma, CD19 expression by immunohistochemistry alone is not a predictor of response to loncastuximab tesirine.
Caimi PF, Hamadani M, Carlo-Stella C, Nickaeen M, Jordie E, Utsey K, Knab T, Zammarchi F, Cucchi D, Pantano S, Havenith K, Wang Y, Boni J. Caimi PF, et al. Among authors: hamadani m. EJHaem. 2023 Nov 30;5(1):76-83. doi: 10.1002/jha2.816. eCollection 2024 Feb. EJHaem. 2023. PMID: 38406517 Free PMC article.
[No title available]
[No authors listed] [No authors listed] PMID: 39112320
Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Patients with Relapsed or Refractory CD20+ B Cell Lymphoma.
Munoz J, Flinn IW, Cohen JB, Sachs J, Exter B, Ranger A, Harris P, Payumo F, Nath R, Hamadani M, Westin JR, Bachanova V. Munoz J, et al. Among authors: hamadani m. Transplant Cell Ther. 2024 Feb;30(2):241.e1-241.e8. doi: 10.1016/j.jtct.2023.10.014. Epub 2023 Oct 26. Transplant Cell Ther. 2024. PMID: 37898374 Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 39112361
Timing of Toxicities and Non-Relapse Mortality Following CAR T Therapy in Myeloma.
Wesson W, Dima D, Suleman N, Saif MSI, Tabak C, Logan E, Davis JA, McGann M, Furqan F, Mohan M, Rashid A, Abdallah AO, Ullah F, Shune L, Mushtaq MU, Raza S, McGuirk J, Hamadani M, Anwer F, Hashmi H, Ahmed N. Wesson W, et al. Among authors: hamadani m. Transplant Cell Ther. 2024 Sep;30(9):876-884. doi: 10.1016/j.jtct.2024.06.012. Epub 2024 Jun 11. Transplant Cell Ther. 2024. PMID: 38871056 Free article.
449 results